ES2170065T3 - Modulacion de la proteina quinasa c por oligonucleotidos. - Google Patents

Modulacion de la proteina quinasa c por oligonucleotidos.

Info

Publication number
ES2170065T3
ES2170065T3 ES93907417T ES93907417T ES2170065T3 ES 2170065 T3 ES2170065 T3 ES 2170065T3 ES 93907417 T ES93907417 T ES 93907417T ES 93907417 T ES93907417 T ES 93907417T ES 2170065 T3 ES2170065 T3 ES 2170065T3
Authority
ES
Spain
Prior art keywords
oligonucleotides
modulation
specifically hybridizable
protein
descirated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93907417T
Other languages
English (en)
Inventor
Frank C Bennett
Nicholas M Dean
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionis Pharmaceuticals Inc
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2170065T3 publication Critical patent/ES2170065T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11013—Protein kinase C (2.7.11.13)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3527—Other alkyl chain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533—Halogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

SE PROPORCIONAN COMPOSICIONES Y METODOS PARA EL TRATAMIENTO Y DIAGNOSIS DE ENFERMEDADES ASOCIADAS CON LA PROTEINA KINASA C. SE PROPORCIONAN OLIGONUCLEOTIDOS QUE SON ESPECIFICAMENTE HIBRIDIZABLES CON ACIDOS NUCLEICOS QUE CODIFICAN PKC. SE PROPORCIONAN OLIGONUCLEOTIDOS ESPECIFICAMENTE HIBRIDIZABLES CON UN LUGAR DE INICIACION DE DESCIFRAMIENTO, REGION NO DESCIFRADA 5'' O REGION NO DESCIFRADA 3''. TAMBIEN SE PROPORCIONAN OLIGONUCLEOTIDOS ESPECIFICAMENTE HIBRIDIZABLES CON UNA ISOZIMA PKC PARTICULAR O GRUPO DE ISOZIMAS. SE DESCRIBEN METODOS DE TRATAMIENTO DE ANIMALES QUE SUFREN ENFERMEDADES RECEPTIVAS A INTERVENCION TERAPEUTICA MEDIANTE LA MODULACION DE LA EXPRESION DE LA PROTEINA KINASA C CON UN OLIGONUCLEOTIDO ESPECIFICAMENTE HIBRIDIZABLE CON ARN O ADN CORRESPONDIENTE A PKC.
ES93907417T 1992-03-16 1993-02-25 Modulacion de la proteina quinasa c por oligonucleotidos. Expired - Lifetime ES2170065T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85285292A 1992-03-16 1992-03-16

Publications (1)

Publication Number Publication Date
ES2170065T3 true ES2170065T3 (es) 2002-08-01

Family

ID=25314390

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93907417T Expired - Lifetime ES2170065T3 (es) 1992-03-16 1993-02-25 Modulacion de la proteina quinasa c por oligonucleotidos.

Country Status (14)

Country Link
US (1) US5703054A (es)
EP (3) EP1126025A3 (es)
JP (1) JP2635216B2 (es)
KR (1) KR0157487B1 (es)
AT (1) ATE212063T1 (es)
AU (1) AU675638B2 (es)
CA (1) CA2132094A1 (es)
DE (1) DE69331467T2 (es)
DK (1) DK0672180T3 (es)
ES (1) ES2170065T3 (es)
FI (2) FI112379B (es)
HU (1) HU217179B (es)
NO (1) NO943438L (es)
WO (1) WO1993019203A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789573A (en) * 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
US7015315B1 (en) * 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US6117847A (en) * 1992-03-16 2000-09-12 Isis Pharmaceuticals, Inc. Oligonucleotides for enhanced modulation of protein kinase C expression
US5922686A (en) * 1992-03-16 1999-07-13 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of protein kinase C
US6537973B1 (en) * 1992-03-16 2003-03-25 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of protein kinase C
US5681747A (en) * 1992-03-16 1997-10-28 Isis Pharmaceuticals, Inc. Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof
AU713740B2 (en) * 1992-03-16 1999-12-09 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of protein kinase C
US6153599A (en) * 1992-03-16 2000-11-28 Isis Pharmaceuticals, Inc. Methoxyethoxy oligonucleotides for modulation of protein kinase C expression
NO180167C (no) * 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
US6645943B1 (en) 1994-10-25 2003-11-11 Hybridon, Inc. Method of down-regulating gene expression
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
AU4205597A (en) * 1996-08-20 1998-03-06 Novartis Ag Methods for prevention of cellular proliferation and restenosis
GB9618376D0 (en) 1996-09-04 1996-10-16 Ciba Geigy Ag Pharmaceutical compositions
US5849902A (en) * 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US5989912A (en) 1996-11-21 1999-11-23 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
EP1080225A4 (en) * 1998-05-21 2004-02-04 Isis Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR THE PULMONAL ADMINISTRATION OF NUCLEIC ACIDS
EP1086116A4 (en) * 1998-05-21 2004-03-17 Isis Pharmaceuticals Inc COMPOSITIONS FOR PULMONARY DELIVERY OF NUCLEIC ACIDS AND METHODS
US6077709A (en) 1998-09-29 2000-06-20 Isis Pharmaceuticals Inc. Antisense modulation of Survivin expression
US6492111B1 (en) 1998-11-25 2002-12-10 Isis Pharmaceuticals, Inc. In situ binary synthesis of biologically effective molecules
DE19956568A1 (de) * 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
AU6071300A (en) * 1999-07-06 2001-01-22 Isis Pharmaceuticals, Inc. Oligonucleotides incorporating both 2-aminoadenine and 5-substituted pyrimidines
US6190869B1 (en) * 1999-10-26 2001-02-20 Isis Pharmaceuticals, Inc. Antisense inhibition of protein kinase C-theta expression
US6852529B1 (en) * 1999-11-08 2005-02-08 University Of South Florida Gloucose-regulated mRNA instability element
US8008071B2 (en) * 1999-11-08 2011-08-30 University Of South Florida Compositions and methods for detecting intracellular glucose and analogs thereof
CN1274072C (zh) * 2000-08-03 2006-09-06 松下电器产业株式会社 无刷电机及其制造方法
US20050182006A1 (en) * 2001-05-18 2005-08-18 Sirna Therapeutics, Inc RNA interference mediated inhibition of protein kinase C alpha (PKC-alpha) gene expression using short interfering nucleic acid (siNA)
US20030054381A1 (en) * 2001-05-25 2003-03-20 Pfizer Inc. Genetic polymorphisms in the human neurokinin 1 receptor gene and their uses in diagnosis and treatment of diseases
US20040014049A1 (en) * 2002-07-19 2004-01-22 Isis Pharmaceuticals Inc. Antisense modulation of protein kinase C-iota expression
FR2864539B1 (fr) * 2003-12-30 2012-10-26 Lvmh Rech Oligonucleotide et son utilisation pour moduler l'expression de la proteine-kinase c isoforme beta-1 comme agent de depigmentation cutanee
WO2024028476A1 (en) * 2022-08-05 2024-02-08 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of th2-mediated diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4511713A (en) * 1980-11-12 1985-04-16 The Johns Hopkins University Process for selectively controlling unwanted expression or function of foreign nucleic acids in animal or mammalian cells
US5034506A (en) * 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
EP0317574A4 (en) * 1986-08-13 1990-11-28 Genetics Institute, Inc. Protein kinase c enzymes
US5098890A (en) * 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
US5138045A (en) * 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
WO1994015621A1 (en) * 1993-01-13 1994-07-21 Arsinur Burcoglu Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states
WO1994018328A1 (en) * 1993-02-06 1994-08-18 Garvan Institute Of Medical Research Protein kinase c (iota)

Also Published As

Publication number Publication date
US5703054A (en) 1997-12-30
KR0157487B1 (ko) 1998-10-15
JP2635216B2 (ja) 1997-07-30
AU675638B2 (en) 1997-02-13
EP1126025A3 (en) 2002-02-13
ATE212063T1 (de) 2002-02-15
EP1126025A2 (en) 2001-08-22
HUT69939A (en) 1995-09-28
EP1310555A2 (en) 2003-05-14
EP0672180B1 (en) 2002-01-16
AU3802593A (en) 1993-10-21
NO943438L (no) 1994-11-11
NO943438D0 (no) 1994-09-15
DE69331467D1 (de) 2002-02-21
EP1310555A3 (en) 2003-08-27
EP0672180A1 (en) 1995-09-20
EP0672180A4 (en) 1997-05-02
JPH07503856A (ja) 1995-04-27
FI112379B (fi) 2003-11-28
FI944276A (fi) 1994-09-15
HU217179B (hu) 1999-12-28
DK0672180T3 (da) 2002-03-04
CA2132094A1 (en) 1993-09-30
KR950700999A (ko) 1995-02-20
WO1993019203A1 (en) 1993-09-30
FI113059B (fi) 2004-02-27
FI20030248A (fi) 2003-02-18
DE69331467T2 (de) 2002-11-07
HU9402657D0 (en) 1994-12-28
FI944276A0 (fi) 1994-09-15

Similar Documents

Publication Publication Date Title
ES2170065T3 (es) Modulacion de la proteina quinasa c por oligonucleotidos.
ATE244506T1 (de) Oligonukleotidmodulation der expression von multiwirkstoff-resistenz -assoziiertem protein
BR9106440A (pt) Oligonucleotideo ou analogo de olifonucleotideo e processo para tratar um animal suspeito de ter uma doenca que se caracteriza pela expressao de gene tat de hiv
PT1117672E (pt) Modulação anti-sentido da expressão de survivina
DE69432315D1 (de) ANTISENSE NUKLEINSÄUREN ZUR VORBEUGUNG UND BEHANDLUNG VON BESCHWERDEN IN WELCHEN DIE EXPRIMIERUNG VON C-erbB-2 EINE ROLLE SPIELT
AU690858B2 (en) Oligonucleotide modulation of cell adhesion
ES2188581T3 (es) Modulacion por oligonucleotidos de la adherencia celular.
WO2002064737A3 (en) Antisense modulation of protein phosphatase 2 catalytic subunit beta expression
ATE214708T1 (de) Kationische mittel zur transfektion von nukleinsäuren
WO2000061786A3 (en) Antisense modulation of pdk-1 expression
WO2003040320A3 (en) Antisense modulation of human collapsin response mediator protein 2 expression

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 672180

Country of ref document: ES